Eupraxia Pharmaceuticals ... (EPRX)
3.94
-0.11 (-2.72%)
At close: Mar 03, 2025, 3:45 PM
4.00
1.63%
After-hours: Mar 03, 2025, 04:01 PM EST
No 1D chart data available
| Bid | 3.78 |
| Market Cap | 140.21M |
| Revenue (ttm) | 2.98M |
| Net Income (ttm) | -24.2M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -4.23 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.45 |
| Volume | 11,123 |
| Avg. Volume (20D) | 13,894 |
| Open | 3.79 |
| Previous Close | 4.05 |
| Day's Range | 3.78 - 3.94 |
| 52-Week Range | 2.20 - 4.48 |
| Beta | 1.48 |
About EPRX
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-1...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 29
Stock Exchange NASDAQ
Ticker Symbol EPRX
Website https://www.eupraxiapharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for EPRX stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 128.66% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 week ago
+10.37%
Eupraxia Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
3 months ago
+10.43%
Eupraxia Pharmaceuticals shares are trading higher after the company unveiled new pharmacokinetic data from its Phase 2A eosinophilic esophagitis program.